 |
|
Folic Acid for the Prevention of Colorectal AdenomasA Randomized Clinical Trial
Bernard F. Cole, PhD;
John A. Baron, MD;
Robert S. Sandler, MD;
Robert W. Haile, DrPh;
Dennis J. Ahnen, MD;
Robert S. Bresalier, MD;
Gail McKeown-Eyssen, PhD;
Robert W. Summers, MD;
Richard I. Rothstein, MD;
Carol A. Burke, MD;
Dale C. Snover, MD;
Timothy R. Church, PhD;
John I. Allen, MD;
Douglas J. Robertson, MD;
Gerald J. Beck, PhD;
John H. Bond, MD;
Tim Byers, MD, MPH;
Jack S. Mandel, PhD, MPH;
Leila A. Mott, MS;
Loretta H. Pearson, MPhil;
Elizabeth L. Barry, PhD;
Judy R. Rees, BM, BCh, MPH, PhD;
Norman Marcon, MD;
Fred Saibil, MD;
Per Magne Ueland, MD;
E. Robert Greenberg, MD; for the Polyp Prevention Study Group
JAMA. 2007;297:2351-2359.
Context Laboratory and epidemiological data suggest that folic acid may have an antineoplastic effect in the large intestine.
Objective To assess the safety and efficacy of folic acid supplementation for preventing colorectal adenomas.
Design, Setting, and Participants A double-blind, placebo-controlled, 2-factor, phase 3, randomized clinical trial conducted at 9 clinical centers between July 6, 1994, and October 1, 2004. Participants included 1021 men and women with a recent history of colorectal adenomas and no previous invasive large intestine carcinoma.
Intervention Participants were randomly assigned in a 1:1 ratio to receive 1 mg/d of folic acid (n = 516) or placebo (n = 505), and were separately randomized to receive aspirin (81 or 325 mg/d) or placebo. Follow-up consisted of 2 colonoscopic surveillance cycles (the first interval was at 3 years and the second at 3 or 5 years later).
Main Outcome Measures The primary outcome measure was occurrence of at least 1 colorectal adenoma. Secondary outcomes were the occurrence of advanced lesions ( 25% villous features, high-grade dysplasia, size 1 cm, or invasive cancer) and adenoma multiplicity (0, 1-2, or 3 adenomas).
Results During the first 3 years, 987 participants (96.7%) underwent colonoscopic follow-up, and the incidence of at least 1 colorectal adenoma was 44.1% for folic acid (n = 221) and 42.4% for placebo (n = 206) (unadjusted risk ratio [RR], 1.04; 95% confidence interval [CI], 0.90-1.20; P = .58). Incidence of at least 1 advanced lesion was 11.4% for folic acid (n = 57) and 8.6% for placebo (n = 42) (unadjusted RR, 1.32; 95% CI, 0.90-1.92; P = .15). A total of 607 participants (59.5%) underwent a second follow-up, and the incidence of at least 1 colorectal adenoma was 41.9% for folic acid (n = 127) and 37.2% for placebo (n = 113) (unadjusted RR, 1.13; 95% CI, 0.93-1.37; P = .23); and incidence of at least 1 advanced lesion was 11.6% for folic acid (n = 35) and 6.9% for placebo (n = 21) (unadjusted RR, 1.67; 95% CI, 1.00-2.80; P = .05). Folic acid was associated with higher risks of having 3 or more adenomas and of noncolorectal cancers. There was no significant effect modification by sex, age, smoking, alcohol use, body mass index, baseline plasma folate, or aspirin allocation.
Conclusions Folic acid at 1 mg/d does not reduce colorectal adenoma risk. Further research is needed to investigate the possibility that folic acid supplementation might increase the risk of colorectal neoplasia.
Trial Registration clinicaltrials.gov Identifier: NCT00272324
Author Affiliations: Departments of Community and Family Medicine (Drs Cole, Baron, Barry, Rees, and Greenberg, and Mss Mott and Pearson) and Medicine (Drs Baron, Rothstein, and Greenberg), Dartmouth Medical School, Hanover, NH; Department of Medicine, University of North Carolina School of Medicine, Chapel Hill (Dr Sandler); Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles (Dr Haile); Departments of Medicine (Dr Ahnen) and Preventive Medicine and Biometrics (Dr Byers), University of Colorado, Denver; Department of Gastrointestinal Medicine and Nutrition, MD Anderson Cancer Center, Houston, Tex (Dr Bresalier); Departments of Public Health Sciences and Nutritional Sciences (Dr McKeown-Eyssen) and Medicine (Drs Marcon and Saibil), University of Toronto, Toronto, Ontario; Division of Gastroenterology/Hepatology, University of Iowa Carver College of Medicine, Iowa City (Dr Summers); Departments of Gastroenterology (Dr Burke) and Quantitative Health Sciences (Dr Beck), The Cleveland Clinic Foundation, Cleveland, Ohio; Department of Pathology, Fairview Southdale Hospital, Edina, Minn (Dr Snover); Division of Environmental Health Sciences, University of Minnesota School of Public Health, Minneapolis (Dr Church); Department of Medicine, Minneapolis Veterans Affairs Medical Center, Minneapolis, Minn (Dr Bond); Minnesota Gastroenterology PA, Plymouth (Dr Allen); Section of Gastroenterology, Department of Veterans Affairs Medical Center, White River Junction, Vt (Dr Robertson); Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, Ga (Dr Mandel); and Section of Pharmacology, Institute of Medicine, University of Bergen and Haukeland University Hospital, Bergen, Norway (Dr Ueland).
RELATED LETTER
Folic Acid and Prevention of Colorectal Adenomas
Young Kwang Chae and Jeong Hyun Yun
JAMA. 2007;298(12):1397.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Folate and Cancer—Timing Is Everything
Cornelia M. Ulrich and John D. Potter
JAMA. 2007;297(21):2408-2409.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The promise and challenges of population strategies of prevention
Michels
Int J Epidemiol 2008;0:dyn176v1-dyn176.
FULL TEXT
Mortality and Cardiovascular Events in Patients Treated With Homocysteine-Lowering B Vitamins After Coronary Angiography: A Randomized Controlled Trial
Ebbing et al.
JAMA 2008;300:795-804.
ABSTRACT
| FULL TEXT
Are we ready for mandatory fortification with vitamin B-12?
Refsum and Smith
Am. J. Clin. Nutr. 2008;88:253-254.
FULL TEXT
Folate status and homocysteine response to folic acid doses and withdrawal among young Chinese women in a large-scale randomized double-blind trial
Hao et al.
Am. J. Clin. Nutr. 2008;88:448-457.
ABSTRACT
| FULL TEXT
B-Vitamin Intake, One-Carbon Metabolism, and Survival in a Population-Based Study of Women with Breast Cancer
Xu et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:2109-2116.
ABSTRACT
| FULL TEXT
Vitamins B2, B6, and B12 and Risk of New Colorectal Adenomas in a Randomized Trial of Aspirin Use and Folic Acid Supplementation
Figueiredo et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:2136-2145.
ABSTRACT
| FULL TEXT
Review: Chemoprevention of esophageal adenocarcinoma
Abrams
Therapeutic Advances in Gastroenterology 2008;1:7-18.
ABSTRACT
Prevalence and effects of gene-gene and gene-nutrient interactions on serum folate and serum total homocysteine concentrations in the United States: findings from the third National Health and Nutrition Examination Survey DNA Bank
Yang et al.
Am. J. Clin. Nutr. 2008;88:232-246.
ABSTRACT
| FULL TEXT
Prediagnostic Plasma Folate and the Risk of Death in Patients With Colorectal Cancer
Wolpin et al.
JCO 2008;26:3222-3228.
ABSTRACT
| FULL TEXT
Shedding Light on Colorectal Cancer Prognosis: Vitamin D and Beyond
Ulrich and Holmes
JCO 2008;26:2937-2939.
FULL TEXT
Does Folic Acid Supplementation Prevent or Promote Colorectal Cancer? Results from Model-Based Predictions
Luebeck et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:1360-1367.
ABSTRACT
| FULL TEXT
Multivitamin-multimineral supplement use and mammographic breast density
Berube et al.
Am. J. Clin. Nutr. 2008;87:1400-1404.
ABSTRACT
| FULL TEXT
Is folic acid good for everyone?
Smith et al.
Am. J. Clin. Nutr. 2008;87:517-533.
ABSTRACT
| FULL TEXT
Long-Term Use of Supplemental Multivitamins, Vitamin C, Vitamin E, and Folate Does Not Reduce the Risk of Lung Cancer
Slatore et al.
Am. J. Respir. Crit. Care Med. 2008;177:524-530.
ABSTRACT
| FULL TEXT
Vitamin and Mineral Supplement Use Among US Adults After Cancer Diagnosis: A Systematic Review
Velicer and Ulrich
JCO 2008;26:665-673.
ABSTRACT
| FULL TEXT
Circulating Concentrations of Folate and Vitamin B12 in Relation to Prostate Cancer Risk: Results from the European Prospective Investigation into Cancer and Nutrition Study
Johansson et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:279-285.
ABSTRACT
| FULL TEXT
Effect of a voluntary food fortification policy on folate, related B vitamin status, and homocysteine in healthy adults
Hoey et al.
Am. J. Clin. Nutr. 2007;86:1405-1413.
ABSTRACT
| FULL TEXT
The Surgeon's Role in Cancer Prevention. The Model in Colorectal Carcinoma
Chu et al.
Ann. Surg. Oncol. 2007;14:3054-3069.
ABSTRACT
| FULL TEXT
Responses of Biomarkers of Folate and Riboflavin Status to Folate and Riboflavin Supplementation in Healthy and Colorectal Polyp Patients (The FAB2 Study)
Powers et al.
Cancer Epidemiol. Biomarkers Prev. 2007;16:2128-2135.
ABSTRACT
| FULL TEXT
Folic Acid and Prevention of Colorectal Adenomas
Chae and Yun
JAMA 2007;298:1397-1397.
FULL TEXT
Folic Acid and Vitamin B-12 Supplementation Does Not Favorably Influence Uracil Incorporation and Promoter Methylation in Rectal Mucosa DNA of Subjects with Previous Colorectal Adenomas
van den Donk et al.
J. Nutr. 2007;137:2114-2120.
ABSTRACT
| FULL TEXT
One-Carbon Metabolism, Colorectal Carcinogenesis, Chemoprevention with Caution
Ziegler and Lim
JNCI J Natl Cancer Inst 2007;99:1214-1215.
FULL TEXT
Folate and cancer prevention: a closer look at a complex picture
Ulrich
Am. J. Clin. Nutr. 2007;86:271-273.
FULL TEXT
Folic Acid to Prevent Recurrence of Colorectal Adenomas?
JWatch Gastroenterology 2007;2007:4-4.
FULL TEXT
Good News and Bad News About Colonic Polyps and Prevention of Colon Cancer: The Bad News
JWatch Oncology and Hematology 2007;2007:2-2.
FULL TEXT
A Temporal Association between Folic Acid Fortification and an Increase in Colorectal Cancer Rates May Be Illuminating Important Biological Principles: A Hypothesis
Mason et al.
Cancer Epidemiol. Biomarkers Prev. 2007;16:1325-1329.
ABSTRACT
| FULL TEXT
Should folic acid fortification be mandatory? Yes
Wald and Oakley
BMJ 2007;334:1252-1252.
FULL TEXT
Folate and Cancer--Timing Is Everything
Ulrich and Potter
JAMA 2007;297:2408-2409.
FULL TEXT
Folic Acid and the Risk for Recurrent Colorectal Adenomas
JWatch General 2007;2007:1-1.
FULL TEXT
|
